+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Relaxation Beverages - Global Strategic Business Report

  • PDF Icon

    Report

  • 371 Pages
  • November 2026
  • Region: Global
  • Market Glass, Inc.
  • ID: 6106231
The global market for Relaxation Beverages was valued at US$438.2 Million in 2025 and is projected to reach US$1.4 Billion by 2032, growing at a CAGR of 17.5% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Relaxation Beverages Market - Key Trends & Drivers Summarized

Why Are Relaxation Beverages Emerging as the New Functional Drink Segment?

Relaxation beverages are gaining global popularity as a distinct functional drink category designed to promote calmness, reduce stress, and improve sleep quality without causing drowsiness or impairing cognition. These drinks typically contain ingredients like L-theanine, GABA, magnesium, melatonin, CBD, and adaptogenic herbs such as ashwagandha or valerian root. Unlike energy drinks that stimulate the nervous system, relaxation beverages act on inhibitory neurotransmitters or stress hormones to deliver a sense of calm and focus. The rise in anxiety, burnout, and sleep-related issues-particularly among urban populations-has driven this trend.

Changing lifestyles, remote work fatigue, and the always-on digital environment have led consumers to seek non-pharmaceutical, everyday solutions to manage mental wellness. Young adults and professionals increasingly opt for these beverages as part of their daily routine-replacing sugary sodas or alcohol-while maintaining productivity and emotional balance. Many brands position these drinks as part of broader wellness rituals, sometimes coupled with yoga, meditation, or mindfulness, expanding their appeal across demographics. Unlike traditional supplements, these products are consumed in socially acceptable formats, such as sparkling drinks, flavored waters, or botanical teas.

Which Formulations and Distribution Channels Are Defining Market Competitiveness?

The most successful formulations in the relaxation beverages market are those that achieve efficacy while maintaining clean-label credentials and good taste. Beverage formulators are investing heavily in microencapsulation and emulsification technologies to stabilize lipophilic ingredients such as CBD or fat-soluble vitamins. Sugar-free and natural sweeteners such as monk fruit and stevia are being used to appeal to health-conscious consumers. Functional ingredient blends often include a mix of amino acids (e.g., taurine, theanine), adaptogens, nootropics, and mild botanicals in calibrated doses to avoid sedative effects.

The D2C (Direct-to-Consumer) model is pivotal in market expansion, with many startups using social media and influencer marketing to create buzz and educate consumers on the science of relaxation. Subscription services are also gaining traction, offering monthly packs of relaxation beverages that promote habitual consumption. At the same time, retail penetration is increasing, particularly in premium grocery chains, health food stores, and even gas station coolers. Innovative packaging-featuring minimalist design, calming color palettes, and eco-friendly materials-is enhancing shelf appeal and reinforcing wellness positioning.

How Are Market Segments and Regulatory Frameworks Evolving Globally?

Segment-wise, beverages targeting general stress reduction constitute the largest share, followed by those marketed for improved sleep quality. Emerging sub-categories include social tonics designed to replace alcohol in leisure settings and workplace-focused drinks aimed at reducing screen fatigue and promoting cognitive relaxation. The inclusion of CBD has added complexity and differentiation, particularly in North America, where its legality and acceptance vary across states and provinces. CBD-infused relaxation beverages are marketed for both mental calm and muscle recovery, overlapping with fitness and wellness segments.

Regulatory compliance varies considerably by region, affecting ingredient choices and marketing claims. In the U.S., many products are sold as dietary supplements rather than beverages to circumvent FDA beverage-specific rules. In Europe, the use of certain botanicals is tightly controlled under EFSA regulations, and claims related to stress or sleep require substantiated evidence. APAC markets, particularly Japan and South Korea, have more established pathways for functional beverages, with FOSHU (Foods for Specified Health Use) approvals driving credibility. Global expansion requires nuanced navigation of these frameworks while maintaining formulation consistency and brand identity.

What Factors Are Driving the Growth of the Relaxation Beverages Market?

The growth in the relaxation beverages market is driven by rising mental health awareness, functional food trends, clean-label expectations, and the desire for pharmaceutical alternatives. Consumers are actively seeking natural, non-addictive ways to manage anxiety, improve sleep, and balance daily stress, especially after the COVID-19 pandemic exposed the fragility of global mental wellness. Relaxation drinks meet this demand with functional, enjoyable, and socially acceptable consumption formats that integrate seamlessly into diverse lifestyles.

Investors are taking note, with many wellness beverage startups receiving seed funding and strategic partnerships with beverage giants. Wellness platforms, biohacking communities, and health influencers are amplifying consumer interest and legitimizing product claims through anecdotal evidence and emerging clinical studies. The convergence of plant-based trends, functional nutrition, and mood-enhancement products ensures that relaxation beverages will remain a dynamic segment within the broader functional drinks category. As consumer focus on holistic health intensifies, relaxation beverages are well-positioned to become staple offerings in retail refrigerators and e-commerce carts worldwide.

Report Scope

The report analyzes the Relaxation Beverages market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:
  • Segments: Type (Relaxation Shots, Relaxation Mixes, Relaxation Drinks); Distribution Channel (Online Distribution Channel, Offline Distribution Channel); Application (Anxiety Application, Insomnia Application, Other Applications)
  • Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Relaxation Shots segment, which is expected to reach US$632.1 Million by 2032 with a CAGR of a 15.6%. The Relaxation Mixes segment is also set to grow at 19.8% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, valued at $119.4 Million in 2025, and China, forecasted to grow at an impressive 22.3% CAGR to reach $300.7 Million by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Relaxation Beverages Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Relaxation Beverages Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Relaxation Beverages Market expected to evolve by 2032?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2032?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as Adapt Drinks, Afterwork Sleep Drinks, Boisson Slow Cow, Inc., Celestial Seasonings, Chillbev and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Relaxation Beverages market report include:

  • Adapt Drinks
  • Afterwork Sleep Drinks
  • Boisson Slow Cow, Inc.
  • Celestial Seasonings
  • Chillbev
  • Dream Water
  • Encha
  • Four Sigmatic
  • Harvest One (Dream Water)
  • iChill Beverages, Inc.
  • Ippodo Tea Co. Ltd.
  • Just Chill
  • Kin Euphorics
  • Leilo
  • Natural Calm
  • Neuro Drinks
  • Om Mushroom
  • PepsiCo (Soulboost)
  • Som Sleep
  • Tranquini GmbH

What Sets This Report Apart From Others?

  • Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
  • Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
  • Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
  • Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
  • Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
  • Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, the report extends market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
  • World Market Trajectories
  • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
  • REM Sleep Behavior Disorders - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Growing Recognition of Sleep Health as a Medical Priority Expands Clinical Focus
  • Rising Geriatric Population Drives Prevalence of REM Sleep Behavior Disorders
  • Improved Access to Sleep Diagnostics Strengthens Early Detection Rates
  • Integration of Polysomnography and Wearables Accelerates Diagnosis Efficiency
  • Increasing Linkages Between Neurodegenerative Disorders and REM Behavior Issues Spur Research
  • Innovation in Non-Invasive Therapies Promotes Patient Acceptance and Treatment Compliance
  • Pharmaceutical Pipeline Developments Throw the Spotlight on Novel Therapeutic Agents
  • Expansion of Sleep Clinics and Centers Supports Specialist Treatment Options
  • Development of Digital Sleep Monitoring Platforms Enhances Patient Monitoring Accuracy
  • Use of AI in Sleep Pattern Analysis Generates Predictive Insight Opportunities
  • Patient Advocacy and Awareness Campaigns Accelerate Diagnosis and Intervention
  • Regulatory Approvals for Targeted Drugs Stimulate Industry Investment
  • Collaborations Between Neurologists and Sleep Specialists Foster Holistic Care Models
  • Genetic and Biomarker Research Improves Understanding of Underlying Mechanisms
  • Adoption of Telehealth Platforms Enables Broader Reach of Sleep Disorder Therapies
  • Clinical Trials Focused on Parkinson's Disease Patients Expand Data on REM Disruptions
  • Expansion of Reimbursement Coverage Encourages Wider Treatment Uptake
  • Inclusion of Sleep Modules in Wellness Platforms Broadens Consumer Awareness
  • Multimodal Treatment Approaches Drive Innovation in Care Delivery
  • Public Health Emphasis on Sleep Quality Positions REM Disorders as High-Priority Segment
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World REM Sleep Behavior Disorders Market Analysis of Annual Sales in US$ Thousand for Years 2020 through 2032
  • Table 2: World Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 3: World Historic Review for REM Sleep Behavior Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 4: World 13-Year Perspective for REM Sleep Behavior Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2020, 2026 & 2032
  • Table 5: World Recent Past, Current & Future Analysis for Clonazepam by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 6: World Historic Review for Clonazepam by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 7: World 13-Year Perspective for Clonazepam by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 8: World Recent Past, Current & Future Analysis for Melatonin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 9: World Historic Review for Melatonin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 10: World 13-Year Perspective for Melatonin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 11: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 12: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 13: World 13-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 14: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 15: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 16: World 13-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 17: World Recent Past, Current & Future Analysis for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 18: World Historic Review for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 19: World 13-Year Perspective for Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 22: World 13-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
III. MARKET ANALYSIS
UNITED STATES
  • REM Sleep Behavior Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
  • Table 23: USA Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 24: USA Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 25: USA 13-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2020, 2026 & 2032
  • Table 26: USA Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 27: USA Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 28: USA 13-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2020, 2026 & 2032
CANADA
  • Table 29: Canada Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 30: Canada Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 31: Canada 13-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2020, 2026 & 2032
  • Table 32: Canada Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 33: Canada Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 34: Canada 13-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2020, 2026 & 2032
JAPAN
  • REM Sleep Behavior Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
  • Table 35: Japan Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 36: Japan Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 37: Japan 13-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2020, 2026 & 2032
  • Table 38: Japan Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 39: Japan Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 40: Japan 13-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2020, 2026 & 2032
CHINA
  • REM Sleep Behavior Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
  • Table 41: China Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 42: China Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 43: China 13-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2020, 2026 & 2032
  • Table 44: China Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 45: China Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 46: China 13-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2020, 2026 & 2032
EUROPE
  • REM Sleep Behavior Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
  • Table 47: Europe Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 48: Europe Historic Review for REM Sleep Behavior Disorders by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 49: Europe 13-Year Perspective for REM Sleep Behavior Disorders by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2020, 2026 & 2032
  • Table 50: Europe Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 51: Europe Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 52: Europe 13-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2020, 2026 & 2032
  • Table 53: Europe Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 54: Europe Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 55: Europe 13-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2020, 2026 & 2032
FRANCE
  • REM Sleep Behavior Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
  • Table 56: France Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 57: France Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 58: France 13-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2020, 2026 & 2032
  • Table 59: France Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 60: France Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 61: France 13-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2020, 2026 & 2032
GERMANY
  • REM Sleep Behavior Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
  • Table 62: Germany Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 63: Germany Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 64: Germany 13-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2020, 2026 & 2032
  • Table 65: Germany Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 66: Germany Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 67: Germany 13-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2020, 2026 & 2032
ITALY
  • Table 68: Italy Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 69: Italy Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 70: Italy 13-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2020, 2026 & 2032
  • Table 71: Italy Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 72: Italy Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 73: Italy 13-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2020, 2026 & 2032
UNITED KINGDOM
  • REM Sleep Behavior Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
  • Table 74: UK Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 75: UK Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 76: UK 13-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2020, 2026 & 2032
  • Table 77: UK Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 78: UK Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 79: UK 13-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2020, 2026 & 2032
SPAIN
  • Table 80: Spain Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 81: Spain Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 82: Spain 13-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2020, 2026 & 2032
  • Table 83: Spain Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 84: Spain Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 85: Spain 13-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2020, 2026 & 2032
RUSSIA
  • Table 86: Russia Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 87: Russia Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 88: Russia 13-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2020, 2026 & 2032
  • Table 89: Russia Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 90: Russia Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 91: Russia 13-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2020, 2026 & 2032
REST OF EUROPE
  • Table 92: Rest of Europe Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 93: Rest of Europe Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 94: Rest of Europe 13-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2020, 2026 & 2032
  • Table 95: Rest of Europe Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 96: Rest of Europe Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 97: Rest of Europe 13-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2020, 2026 & 2032
ASIA-PACIFIC
  • REM Sleep Behavior Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
  • Table 98: Asia-Pacific Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 99: Asia-Pacific Historic Review for REM Sleep Behavior Disorders by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 100: Asia-Pacific 13-Year Perspective for REM Sleep Behavior Disorders by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2020, 2026 & 2032
  • Table 101: Asia-Pacific Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 102: Asia-Pacific Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 103: Asia-Pacific 13-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2020, 2026 & 2032
  • Table 104: Asia-Pacific Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 105: Asia-Pacific Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 106: Asia-Pacific 13-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2020, 2026 & 2032
AUSTRALIA
  • REM Sleep Behavior Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2026 (E)
INDIA
  • REM Sleep Behavior Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2026 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • REM Sleep Behavior Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2026 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • REM Sleep Behavior Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2026 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • REM Sleep Behavior Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2026 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Adapt Drinks
  • Afterwork Sleep Drinks
  • Boisson Slow Cow, Inc.
  • Celestial Seasonings
  • Chillbev
  • Dream Water
  • Encha
  • Four Sigmatic
  • Harvest One (Dream Water)
  • iChill Beverages, Inc.
  • Ippodo Tea Co. Ltd.
  • Just Chill
  • Kin Euphorics
  • Leilo
  • Natural Calm
  • Neuro Drinks
  • Om Mushroom
  • PepsiCo (Soulboost)
  • Som Sleep
  • Tranquini GmbH

Table Information